REFERENCES
- The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020, C JL Murray, A D Lopez. Harvard University Press, Cambridge 1996
- Angst J. Bipolar disorder—a seriously underestimated health burden. Eur Arch Psychiatry Clin Neurosci 2004; 254: 59–60, [PUBMED], [INFOTRIEVE], [CSA]
- Weissman M M, Bland R C, Camino G H. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996; 276: 293–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hirschfeld R M, Calabrese J R, Weissman M M. Screening for bipolar disorder in the community. J Clin Psychiatry 2003; 64: 53–9, [PUBMED], [INFOTRIEVE], [CSA]
- Judd L L, Akiskal H S. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003; 73: 123–31, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hirschfeld R M, Lewis L, Vornik L A. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003; 64: 161–74, [PUBMED], [INFOTRIEVE], [CSA]
- Judd L L, Akiskal H S, Schettler P J. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Judd L L, Akiskal H S, Schettler P J. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kupfer D J, Frank E, Grochocinski V J. Stabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatr 2000; 12: 110–4, [CSA]
- Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003; 17: 491–511, [PUBMED], [INFOTRIEVE], [CSA]
- Baldessarini R J, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 2003; 64: 44–52, suppl 5[PUBMED], [INFOTRIEVE], [CSA]
- Joffe R T, Mac Queen G M, Marriott M, Robb J, Begin H, Young L T. Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand 2002; 105: 427–30, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ghaemi S N, Boiman E E, Goodwin F K. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000; 61: 804–8, [PUBMED], [INFOTRIEVE], [CSA]
- Sachs G S, Koslow C L, Ghaemi S N. The treatment of bipolar depression. Bipolar Disord 2000; 2: 256–60, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Perris C. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand 1966; 42: 1–188, suppl 194[CSA]
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. APA, Washington, DC 1980
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. text rev, APA, Washington, DC 2000
- Goodwin F K, Jamison K R. Manic-depressive illness. Oxford University Press, London 1990
- Akiskal H S, Walker P, Puzantian V R, King D, Rosenthal T L, Dranon M. Bipolar outcome in the course of depressive illness. Phenomenologic, familial, and pharmacologic predictors. J Affect Disord 1983; 5: 115–28, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Winokur G, Coryell W, Keller M, Endicott J, Leon A. A family study of manic-depressive (bipolar I) disease. Is it a distinct illness separable from primary unipolar depression? Arch Gen Psychiatry 1995; 52: 367–73, [CSA]
- Benazzi F. Depression with DSM-IV atypical features: a marker for bipolar II disorder. Eur Arch Psychiatry Clin Neurosci 2000; 250: 53–5, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mitchell P B, Wilhelm K, Parker G, Austin M -P, Rutgers P, Malhi G S. The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J Clin Psychiatry 2001; 62: 212–6, [PUBMED], [INFOTRIEVE], [CSA]
- Perugi G, Akiskal H S, Lattanzi L. The high prevalence of “soft” bipolar (II) features in atypical depression. Compr Psychiatry 1998; 39: 63–71, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sharma V. Loss of response to antidepressants and subsequent refractoriness: diagnostic issues in a retrospective case series. J Affect Disord 2001; 64: 99–106, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sharma V, Khan M, Smith A. A closer look at treatment resistant depression: is it due to a bipolar diathesis?. J Affect Disord 2005; 84: 251–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Akiskal H S. Searching for behavioral indicators of bipolar II in patients presenting with major depressive episodes: the “red sign,” the “rule of three” and other biographic signs of temperamental extravagance, activation and hypomania. J Affect Disord 2005; 84: 279–90, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wong I C, Besag F M, Santosh P J, Murray M L. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf 2004; 27: 991–1000, [PUBMED], [INFOTRIEVE], [CSA]
- Chun B J, Dunner D L. A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. Bipolar Disord 2004; 6: 32–42, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549–50, [PUBMED], [INFOTRIEVE], [CSA]
- Akiskal H S, Hantouche E G, Allilaire J F. Validating antidepressant-associated hypomania (bipolar III): a systematic comparison with spontaneous hypomania (bipolar II). J Affect Disord 2003; 73: 65–74, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hirschfeld R M, Williams J B, Spitzer R L. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000; 157: 1873–5, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Manning J S, Haykal R F, Akiskal H S. The role of bipolarity in depression in the family practice setting. Psychiatr Clin North Am 1999; 22: 689–703, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gijsman H J, Geddes J R, Rendell J M, Nolen W A, Goodwin G M. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161: 1537–47, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thase M E, Sachs G S. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol Psychiatry 2000; 48: 558–72, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ghaemi S N, Rosenquist K J, Ko J Y, Baldassano C F, Kontos N J, Baldessarini R J. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2004; 161: 163–5, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bottlender R, Rudolf D, Jager M, Strauss A, Möller H J. Are bipolar I depressive patients less responsive to treatment with antidepressants than unipolar depressive patients? Results from a case control study. Eur Psychiatry 2002; 17: 200–5, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ghaemi S N, Hsu D J, Soldani F, Goodwin F K. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003; 5: 421–33, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Möller H J, Bottlender R, Grunze H, Strauss A, Wittmann J. Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression?. J Affect Disord 2001; 67: 141–6, [CROSSREF], [CSA]
- American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1–50, suppl 4[CROSSREF], [CSA]
- Sachs G S, Printz D J, Kahn D A, Carpenter D, Docherty J P. The expert consensus guideline series. Medication treatment of bipolar disorder. Postgrad Med Spec Rep 2000. Apr, 2000; 1–104
- Keck P E, Perlis R H, Otto M W, Carpenter D, Ross R, Docherty J P. The expert consensus guideline series. Treatment of bipolar disorder 2004. Postgrad Med Spec Rep. December, 2004; 1–119
- Suppes T, Dennehy E B, Swann A C. Report of the Texas consensus conference panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002; 63: 288–99, [PUBMED], [INFOTRIEVE], [CSA]
- Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 2004; 38: 280–305, [CROSSREF], [CSA]
- Calabrese J R, Kasper S, Johnson G. International consensus group on bipolar I depression treatment guidelines. J Clin Psychiatry 2004; 65: 571–9, [PUBMED], [INFOTRIEVE], [CSA]
- Goodwin G M. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149–73, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Grunze H, Kasper S, Goodwin G. World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Bipolar Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry 2002; 3: 115–24, [PUBMED], [INFOTRIEVE], [CSA]
- Keck P E, Jr, McElroy S L. New approaches in managing bipolar depression. J Clin Psychiatry 2003; 64: 13–8, suppl 1[PUBMED], [INFOTRIEVE], [CSA]
- Nemeroff C B, Evans D L, Gyulai L. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158: 906–12, [PUBMED], [INFOTRIEVE], [CSA]
- Sachs G S, Lafer B, Stoll A L. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391–3, [PUBMED], [INFOTRIEVE], [CSA]
- Blanco C, Laje G, Olfson M, Marcus S C, Pincus H A. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002; 159: 1005–10, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Goodwin F K, Fireman B, Simon G E, Hunkeler E M, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 1467–73, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Davis L, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005; 85: 259–66, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sachs G, Altshuler L, Ketter T. Divalproex sodium versus placebo for the treatment of bipolar depression. Poster presented at the American College of Neuropsychopharmacology, Waikoloa, HI, December, 2001
- Swann A C, Bowden C L, Calabrese J R, Dilsaver S C, Morris D D. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002; 26: 530–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gyulai L, Bowden C L, McElroy S L. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003; 28: 1374–82, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Post R M, Frye M AQ, Denicoff K D, Leverich G S, Kimbrell T A, Dunn R T. Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology 1998; 19: 206–19, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hirschfeld R M, Kasper S. A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2004; 7: 507–22, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ketter T A, Kalali A H, Weisler R H. SPD417 Study Group. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65: 668–73, [PUBMED], [INFOTRIEVE], [CSA]
- Marangell L B, Martinez J M, Ketter T A. STEP-BD Investigators. Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD. Bipolar Disord 2004; 6: 139–43, [PUBMED], [INFOTRIEVE], [CSA]
- Calabrese J R, Bowden C L, Sachs G S, Ascher J A, Monaghan E, Rudd G D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60: 79–88, [PUBMED], [INFOTRIEVE], [CSA]
- Frye M A, Ketter T A, Kimbrell T A. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607–14, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Calabrese J R, Suppes T, Bowden C L. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61: 841–50, [PUBMED], [INFOTRIEVE], [CSA]
- Calabrese J, Sachs G, Hirschfeld R MA. Efficacy and safety of lamotrigine in acute bipolar depression: findings from three completed studies. Presented at the 45th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June, 2005
- Brown E, Williamson D, Deldar A, Keck P E, Adams D H. Olanzapine-fluoxetine combination versus lamotrigine for bipolar depression. Presented at the 45th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June, 2005
- Bowden C L, Calabrese J R, Sachs G. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392–400, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Calabrese J R, Bowden C L, Sachs G, for the Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013–24, [PUBMED], [INFOTRIEVE], [CSA]
- Hahn C G, Gyulai L, Baldassano C F, Lenox R H. The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry 2004; 65: 791–804, [PUBMED], [INFOTRIEVE], [CSA]
- Goodwin G M, Bowden C L, Calabrese J R. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432–41, [PUBMED], [INFOTRIEVE], [CSA]
- Ketter T A, Calabrese J R. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 2002; 63: 146–51, [PUBMED], [INFOTRIEVE], [CSA]
- Bowden C L, Asnis G M, Ginsberg L D, Bentley B, Leadbetter R, White R. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004; 27: 173–84, [PUBMED], [INFOTRIEVE], [CSA]
- Calabrese J R, Sullivan J R, Bowden C L. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002; 63: 1012–9, [PUBMED], [INFOTRIEVE], [CSA]
- Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush A J. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164–9, [PUBMED], [INFOTRIEVE], [CSA]
- Berk M, Dodd S. Efficacy of atypical antipsychotics in bipolar disorder. Drugs 2005; 65: 257–69, [PUBMED], [INFOTRIEVE], [CSA]
- Kennedy S H, Lam R W. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord 2003; 5: 36–47, suppl 2[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tohen M, Jacobs T G, Grundy S L. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000; 57: 841–9, (erratum in Arch Gen Psychiatry 2002;59:91)[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chengappa K N, Baker R W, Shao L. Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord 2003; 5: 1–5, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vieta E, Calabrese J R, Hennen J. Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. J Clin Psychiatry 2004; 65: 1420–8, [PUBMED], [INFOTRIEVE], [CSA]
- Tohen M, Chengappa K N, Suppes T. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337–45, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Baker R W, Tohen M, Fawcett J. Acute dysphoric mania: treatment response to olanzapine versus placebo. J Clin Psychopharmacol 2003; 23: 132–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Baker R W, Brown E, Akiskal H S. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry 2004; 185: 472–8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tohen M, Vieta E, Calabrese J. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079–88, (erratum in Arch Gen Psychiatry2004;61:176)[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shi L, Namjoshi M A, Swindle R. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther 2004; 26: 125–34, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Calabrese J R, Keck P E, Jr, Macfadden W. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351–60, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hirschfeld R M, Keck P E, Jr. Kramer M Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004; 161: 1057–65, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zajecka J, Murray S, Ramey T, Mandel F S. Efficacy of ziprasidone in dysphoric mania. Presented at the 45th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June, 2005
- Keck P E, Jr, Marcus R, Tourkodimitris S. Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651–8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Keck P E, McElroy S L. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry 2003; 64: 1426–35, [PUBMED], [INFOTRIEVE], [CSA]
- Brown R R, Estoup M W. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol 2005; 20: 105–12, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Meyer J M, Koro C E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1–17, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Melkersson K, Dahl M L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64: 701–23, [PUBMED], [INFOTRIEVE], [CSA]
- Zhang W, Perry K W, Wong D T. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000; 23: 250–62, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bottlender R, Rudolf D, Strauss A, Möller H J. Mood stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 2001; 63: 79–83, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thase M E, Bhargava M, Sachs G S. Treatment of bipolar depression: current status, continued challenges, and the STEP-BD approach. Psychiatr Clin North Am 2003; 26: 495–518, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cohn J B, Collins G, Ashbrook E, Wenicke J F. A comparison of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4: 313–22, [PUBMED], [INFOTRIEVE], [CSA]
- Young L T, Joffe R T, Robb J C, MacQueen G M, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157: 124–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vieta E, Martinhez-Aran A, Goikolea J M. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63: 508–12, [PUBMED], [INFOTRIEVE], [CSA]
- Shelton R C, Stahl S M. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004; 65: 1715–9, [PUBMED], [INFOTRIEVE], [CSA]
- Fagiolini A, Buysse D J, Frank E, Houck P R, Luther J F, Kupfer D J. Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression. J Clin Psychopharmacol 2001; 21: 474–8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thase M E, Haight B R, Richard N. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a pooled analysis of original data from seven randomized controlled trials. J Clin Psychiatry, in press[CSA]
- McIntyre R S, Mancini D A, McCann S, Srinivasan J, Sagman D, Kennedy S H. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002; 4: 207–13, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thase M E, Entsuah R A, Rudolph R L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234–41, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002; 180: 396–404, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thase M E, Friedman E S, Howland R H. Venlafaxine and treatment-resistant depression. Depress Anxiety 2000; 12: 55–62, suppl 1[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Post R M, Leverich G S, Altshuler L L. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord 2003; 5: 310–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thase M E. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59: 502–8, [PUBMED], [INFOTRIEVE], [CSA]
- Buckley N A, Faunce T A. ‘Atypical’ antidepressants in overdose: clinical considerations with respect to safety. Drug Saf 2003; 26: 539–51, [PUBMED], [INFOTRIEVE], [CSA]
- Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse A H. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. Br J Psychiatry 2004; 184: 41–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nemeroff C B, Schatzberg A F, Goldstein D J. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36: 106–32, [PUBMED], [INFOTRIEVE], [CSA]
- Thase M E. Comparing the efficacy of the newer antidepressants. Neuvas Perspectivas en la Depresión, I Gilaberte. Aula Médica Ediciones, Madrid 2004; 253–86
- Perahia D, Pritchett Y L, Lee T C, Tran P F. Comparing duloxetine and venlafaxine in the treatment of major depressive disorder using a global benefit-risk approach. Presented at the 45th annual meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June, 2005
- Thase M E, Tran P V, Wiltse C, Pangallo B A, Mallinckrodt C, Detke M J. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005; 25: 132–40, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vaishnavi S N, Nemeroff C B, Plott S J, Rao S G, Kranzler J, Owens M J. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004; 55: 320–2, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sachs G S, Thase M E, Otto M W. Rationale, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2003; 53: 1028–42, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thase M E, Trivedi M H, Rush A J. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12: 185–219, [PUBMED], [INFOTRIEVE], [CSA]
- Himmelhoch J M, Fuchs C Z, Symons B J. A double-blind study of tranylcypromine treatment of major anergic depression. J Nerv Ment Dis 1982; 170: 628–34, [PUBMED], [INFOTRIEVE], [CSA]
- Himmelhoch J M, Thase M E, Mallinger A G, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 2001; 148: 910–6, [CSA]
- Thase M E, Mallinger A G, McKnight D, Himmelhoch J M. Treatment of imipramine-resistant recurrent depression: IV. A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149: 195–8, [PUBMED], [INFOTRIEVE], [CSA]
- Beasley C M, Masica D N, Heiligenstein J H, Wheadon D E, Zerbe R L. Possible monoamine oxidase inhibitor-serotonin reuptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993; 13: 312–20, [PUBMED], [INFOTRIEVE], [CSA]
- Lotufo-Neto F, Trivedi M, Thase M E. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999; 20: 226–47, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Angst J, Stabl M. Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology 1992; 106: S109–13, [PUBMED], [INFOTRIEVE], [CSA]
- Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand 2001; 104: 104–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Amsterdam J D. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003; 64: 208–14, [PUBMED], [INFOTRIEVE], [CSA]
- Altshuler L L, Frye M A, Gitlin M J. Acceleration and augmentation strategies for treating bipolar depression. Biol Psychiatry 2003; 53: 691–700, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bauer M, London E D, Rasgon N. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol Psychiatry 2005; 10: 456–69, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Carlson P J, Merlock M C, Suppes T. Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation. Bipolar Disord 2004; 6: 416–20, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Goldberg J F, Burdick K E, Endick C J. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cassano P, Lattanzi L, Soldani F. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety 2004; 20: 131–8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sohn C H, Lam R W. Treatment of seasonal affective disorder: unipolar versus bipolar differences. Curr Psychiatry Rep 2004; 6: 478–85, [PUBMED], [INFOTRIEVE], [CSA]
- Black D W, Winokur G, Nasrallah A. ECT in unipolar and bipolar disorders: a naturalistic evaluation of 460 patients. Convuls Ther 1986; 2: 231–7, [PUBMED], [INFOTRIEVE], [CSA]
- Thase M E. The role of psychotherapy in the management of bipolar disorder. Handbook of bipolar disorder, S Kasper, R MA Hirschfeld. Marcel Dekker, New York, in press
- Lam D H, Watkins E R, Hayward P. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry 2003; 60: 145–52, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Frank E, Kupfer D J, Thase M E. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry, in press[CSA]
- Miklowitz D J, George E L, Richards J A, Simoneau T L, Suddath R L. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003; 60: 904–12, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Baumgartner A. Thyroxine and the treatment of affective disorders: an overview of the results of basic and clinical research. Int J Neuropsychopharmacol 2000; 2: 149–65, [CROSSREF], [CSA]
- Frye M A, Denicoff K D, Bryan A L. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry 1999; 156: 1909–14, [PUBMED], [INFOTRIEVE], [CSA]
- Cole D P, Thase M E, Mallinger A G. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry 2002; 159: 116–21, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Goldberg J F, Whiteside J E. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. J Clin Psychiatry 2002; 63: 791–5, [PUBMED], [INFOTRIEVE], [CSA]
- Weiss R D. Treating patients with bipolar disorder and substance dependence: lessons learned. J Subst Abuse Treat 2004; 27: 307–12, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Salloum I H, Thase M E. Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord 2000; 2: 269–80, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hadjipavlou G, Mok H, Yatham L N. Pharmacotherapy of bipolar II disorder: a critical review of current evidence. Bipolar Disord 2004; 6: 14–25, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yatham L N. Diagnosis and management of patients with bipolar II disorder. J Clin Psychiatry 2005; 66: 13–7, suppl 1[PUBMED], [INFOTRIEVE], [CSA]
- Akiskal H S, Benazzi F. Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II?. J Affect Disord 2005; 84: 209–17, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hantouche E G, Akiskal H S. Bipolar II vs. unipolar depression: psychopathologic differentiation by dimensional measures. J Affect Disord 2005; 84: 127–32, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kupfer D J, Carpenter L L, Frank E. Is bipolar II a unique disorder?. Compr Psychiatry 1988; 29: 228–36, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Amsterdam J D, Shults J, Brunswick D J, Hundert M. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression—low manic switch rate. Bipolar Disord 2004; 6: 75–81, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Amsterdam J D, Brunswick D J. Antidepressant monotherapy for bipolar type II major depression. Bipolar Disord 2003; 5: 388–95, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Amsterdam J D, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord 2000; 59: 225–9, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zarate C A, Jr, Payne J L, Singh J. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54–60, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Geddes J R, Burgess S, Hawton K, Jamison K, Goodwin G M. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217–22, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sachs G S, Thase M E. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry 2000; 48: 573–81, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Altshuler L, Kiriakos L, Calcagno J. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 2001; 62: 612–6, [PUBMED], [INFOTRIEVE], [CSA]
- Altshuler L, Suppes T, Black D. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003; 160: 1252–62, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]